论文部分内容阅读
目的探讨纤溶酶原激活物抑制剂1(PAI-1)与肝纤维化发生的关系。方法对30例乙型肝炎患者行肝脏活检,明确肝纤维化分级。正常肝组织3例,1~2级肝纤维化12例,3级肝纤维化8例,肝硬化7例。采用免疫组化及半定量分析方法,检测PAI-1在肝纤维化组织中的表达。结果在正常肝脏中,PAI-1仅在汇管区细胞浆内有少量表达;肝纤维化组PAI-1表达均高于正常肝组织(P<0.05),且随纤维化程度而加重(P<0.05)。在纤维化肝脏,PAI-1主要分布于细胞浆。结论 PAI-1在肝纤维化组织中高表达可能在肝纤维化的发生中起重要作用。
Objective To investigate the relationship between plasminogen activator inhibitor 1 (PAI-1) and hepatic fibrosis. Methods Thirty patients with hepatitis B underwent liver biopsy to confirm the grade of liver fibrosis. 3 cases of normal liver tissue, 1 ~ 2 grade liver fibrosis in 12 cases, 3 grade liver fibrosis in 8 cases, cirrhosis in 7 cases. The expression of PAI-1 in hepatic fibrosis tissue was detected by immunohistochemistry and semi-quantitative analysis. Results In normal liver, PAI-1 expression was only slightly expressed in the cytoplasm of the portal area. The expression of PAI-1 in liver fibrosis group was higher than that in normal liver tissue (P <0.05), and aggravated with the degree of fibrosis (P < 0.05). In fibrotic liver, PAI-1 is mainly distributed in the cytoplasm. Conclusion The high expression of PAI-1 in hepatic fibrosis may play an important role in the pathogenesis of hepatic fibrosis.